Authors: Jia Z, Li J, Liu J, Han W, Xu W, Lu X.
DOI: 10.3389/fonc.2025.1694343
Abstract Summary
Abnormal serum free light chain (FLC) levels in diffuse large B-cell lymphoma patients correlate with aggressive disease features and poorer survival outcomes. In this 259-patient study, abnormal FLC associated with advanced stage, elevated LDH, and bone marrow involvement. Monoclonal FLC particularly predicted reduced survival in non-germinal center subtypes, suggesting FLC assessment could serve as an accessible biomarker for risk stratification.
Why Brain? ðŸ§
Abnormal serum free light chains predict worse outcomes in diffuse large B-cell lymphoma patients, especially monoclonal patterns in non-germinal center subtypes, offering a simple biomarker for risk assessment.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
